Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery

disease: a reverse Mendelian randomization study

Short title: Metabolic features of genetic liability to T2D and CAD

Madeleine L Smith[1,2], Caroline J Bull[1,2,3], Michael V Holmes[1,2,] George Davey Smith[1,2], Emma L

Anderson[1,2], Joshua A Bell[1,2]

[1] Medical Research Council, Integrative Epidemiology Unit, University of Bristol, Bristol, UK

[2] Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK

[3] School of Translational Health Sciences, University of Bristol, Bristol, UK

Corresponding author: Madeleine L Smith, Oakfield House, University of Bristol, UK, BS8 2BN,

email: madeleine.smith@bristol.ac.uk, ORCID ID: 0000-0003-0215-9691

Abstract words: 358; **Main text words**: 4518; **References**: 71; **Tables & Figures**: 7;

Supplementary items: 7 tables, 12 figures.

Keywords: Type 2 diabetes; Coronary artery disease; Genetics; Mendelian randomization;

Metabolism; NMR; Epidemiology; UK Biobank

ABSTRACT

Type 2 diabetes (T2D) and coronary artery disease (CAD) both have known genetic determinants, but the mechanisms through which their associated genetic variants lead to disease onset remain poorly understood. Here, we used large-scale metabolomics data to directly compare the metabolic features of genetic liability to T2D and to CAD. We performed two-sample reverse Mendelian randomization (MR) to estimate effects of genetic liability to T2D and CAD on 249 circulating metabolites from targeted nuclear magnetic resonance spectroscopy in the UK Biobank (N=118,466). We examined the potential for medication use to distort effect estimates by examining effects of disease liability on metformin and statin use and by conducting age-stratified metabolite analyses. Using inverse variance weighted (IVW) models, higher genetic liability to T2D was estimated to decrease high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) (e.g., HDL-C: -0.05 SD; 95% CI -0.07, -0.03, per doubling of liability), whilst increasing all triglyceride groups and branched chain amino acids (BCAAs). Estimates for CAD liability suggested an effect on reducing HDL-C as well as raising very-low density lipoprotein cholesterol (VLDL-C) and LDL-C, and LDL triglycerides. Liability to each disease was estimated to decrease apolipoprotein-A1, whilst only CAD liability was estimated with IVW to increase apolipoprotein-B (0.10 SD; 95% CI 0.03, 0.17). In pleiotropy-robust sensitivity models, T2D liability was still estimated to increase BCAAs, but several effect estimates for higher CAD liability reversed and supported decreased LDL-C and apolipoprotein-B. Estimated effects of CAD liability differed uniquely and substantially by age for non-HDL-C traits in particular, with, e.g., pleiotropy-robust models suggesting that higher CAD liability lowers LDL-C only at older ages when use of statins is common. Our results from pleiotropy-robust models support largely distinct metabolic features of genetic liability to T2D and to CAD, particularly higher BCAAs in T2D and lower LDL-C and apolipoprotein-B in CAD. Such apparently favourable effects of CAD liability differ substantially by age and likely reflect mediation by statin use in adulthood.

INTRODUCTION

Globally, overall incidence rates of type 2 diabetes (T2D) and coronary artery disease (CAD) are increasing in parallel, together affecting over 500 million adults.(1,2) Both diseases have roots in disordered metabolism, but they differ in their life course development and clinical presentation. Genome-wide association studies (GWAS) have provided robust evidence that both T2D and CAD have genetic influences,(3,4) but the mechanisms through which the associated genetic variants increase disease risk remain poorly understood.

Recent advances in metabolomics technologies involve the simultaneous quantification of hundreds of molecular metabolites from a single biological sample, enabling detailed insight into the metabolic features of cardiometabolic diseases and their potential underlying mechanisms.(5) The application of metabolomics in observational epidemiological studies has helped to identify metabolites involved in the pathogenesis of T2D, or that might contribute to T2D incidence.(6–16) For example, a recent meta-analysis identified associations of incident T2D with differences in several lipid and non-lipid metabolites, including higher levels of branched chain amino acids (BCAAs), some fatty acids and acylcarnitines, amongst others.(17) For CAD, metabolomics in observational studies has helped to identify key metabolic characteristics of the disease,(18–25) to predict and diagnose CAD,(26–29) and to predict outcomes and mortality in CAD patients.(30–32) However, observational studies are limited in their ability to infer whether metabolic traits are causal, rather than just predictive for disease, as these studies are liable to bias due to residual confounding by lifestyle factors and other diseases.

Mendelian randomization (MR), a genetic epidemiological approach that uses genetic variants associated with modifiable exposures to estimate the unbiased effects of such exposures on outcomes,(33) has been applied to investigate associations between lipid levels and T2D and

CAD (34–37), with the two diseases appearing to have differing lipid aetiology: higher low-

density lipoprotein cholesterol (LDL-C) and triglycerides increase CAD risk, whereas higher LDL

and high-density lipoprotein cholesterol (HDL-C) reduce T2D risk.(36) More recently, MR has

been used in 'reverse' to estimate effects of genetic liability for disease and potential

biomarkers, to reveal features of the developing disease process, which include both causal and

non-causal factors for disease incidence.(38) Using reverse-MR, higher genetic liability to T2D

diagnosed in adulthood has been estimated to decrease total lipid content in HDL particles, as

well as increase BCAA and inflammatory glycoprotein acetyl levels, as early as 8 years of

age.(39) Higher genetic liability to CAD has also been estimated to affect circulating metabolite

levels in early life, especially higher very-low-density lipoprotein (VLDL) and total lipids in

LDL.(40) These MR studies in children have the advantage of low disease prevalence (and

therefore little reverse causality), and low medication use, so are useful for identifying causal

factors. Studies in older adults are better for identifying predictors of disease, as there is a

greater burden of prevalent disease, however increased medication use with age has the

potential to distort results. Previous reverse-MR studies of the impact of genetic liability to T2D

or CAD on metabolic traits are limited by their small sample sizes; cohort studies of ~5,000

participants or GWAS of less than ~25,000 adults. Moreover, the metabolic profiles of genetic

liability to T2D and CAD have not been directly compared within the same analytical setting, and

so the ways in which these profiles differ have not yet been revealed.

Here, we compare the metabolic features of genetic liability to T2D and to CAD using a reverse-

MR framework, with the aim of revealing the pattern of metabolic traits which characterise the

development of each disease. We used the largest, most recent summary-level GWAS data on

circulating metabolites measured using targeted metabolomics (N~120,000) from the

population-based UK Biobank cohort study, representing a 5-fold larger sample size than

previous studies. To examine the potential for effect estimates to be distorted by medication

use, we examined the effects of T2D and CAD liability on the use of metformin and statins, and

repeated analyses using data from age stratified GWAS of metabolites, given that medication

use differs markedly by age. We also estimated the effects of disease liability on more distal

lifestyle-related factors, including adiposity, smoking, and alcohol consumption.

METHODS

Genetic instruments for T2D liability and CAD liability

T2D liability

We identified single nucleotide polymorphisms (SNPs) that were independently associated with

T2D at $P < 5 \times 10^{-8}$ from a large-scale GWAS meta-analysis combining data from 32 GWAS,

including 74,124 T2D cases and 824,006 controls of European ancestry.[3] Across included

studies, female sex ranged from 37 to 64% and mean (SD) age range was 23.9 (2.1) to 61.3

(2.9) years. T2D was diagnosed across included studies using a range of criteria, including use

of oral diabetes medication, diagnostic fasting glucose or HbA1c levels, or self-report. The T2D

GWAS was conducted with and without adjustment for BMI, and we used the 231 SNPs

identified in the non-BMI-adjusted GWAS to reduce potential for collider bias.[41] For variants

that were in linkage disequilibrium (LD) based on $R^2 > 0.001$, the SNP with the lowest P-value in

each set of variants in LD was retained. This left 167 independent SNPs associated with T2D

(**Supplementary Table 1**) for inclusion in our reverse-MR analysis.

CAD liability

SNPs for CAD were identified in a large-scale GWAS meta-analysis of 10 GWAS conducted

among middle-aged adults, with study-specific sample and variant filters applied and adjustment

for study-specific covariates. The study had a total sample of 181,522 cases among 1,165,690

study participants, who were 46% female and largely of European ancestry (>95%). Potential

ancestry effects were accounted for by transethnic comparison with a GWAS from Biobank

Japan. Case status was defined based on relevant hospital codes for prevalent or incident CAD.

The GWAS detected 241 genetic variants independently associated with CAD at $P < 5 \times 10^{-8}$.

For variants that were in LD based on $R^2 > 0.001$, the SNP with the lowest P-value in each set

of variants in LD was retained, leaving 145 SNPs (**Supplementary Table 1**).

Outcome data on circulating metabolites and medication use

Summary statistics from GWAS of circulating metabolites conducted among European

participants of the UK Biobank study were used. Details of the UK Biobank design, participants,

genomic quality control (QC) and its strengths and limitations have been reported

previously.[42–44] Briefly, 502,549 adults aged 40-69 years were recruited between 2006-2010

via 22 assessment centres across England, Wales, and Scotland. Non-fasting EDTA plasma

samples from a random subset of participants (N = 118,466) were analysed for levels of 249

metabolic traits (165 concentrations and 84 derived ratios) using targeted high-throughput

proton nuclear magnetic resonance (^{1}H-NMR) spectroscopy (Nightingale Health Ltd; biomarker

quantification version 2020).[45] These metabolic traits comprised routine lipids, lipoprotein

subclass profiling, fatty acid composition and various low-molecular-weight metabolites

including BCAAs, ketone bodies, glycolysis-related traits and inflammatory glycoprotein acetyls.

All metabolic trait measurements were normalized and standardised prior to analyses using

rank-based inverse normal transformation. Metabolite GWAS were adjusted for genotype array,

sex, and fasting time. We also included C-reactive protein (CRP) for comparison with

glycoprotein acetyls, measured in UK Biobank via the same blood samples, analyzed by

immunoturbidimetric-high sensitivity analysis on a Beckman Coulter AU5800 (N = 469,772).

Statins and metformin are commonly prescribed medications for the prevention/treatment of

CAD and T2D, respectively, particularly among adults identified as having higher risk.[46]

These medications can alter the levels of circulating metabolites (47,48) and thus may distort

associations of genetic liability to T2D and CAD with metabolites (via mediation). We therefore

additionally estimated the effects of T2D and CAD liability on the self-reported use of statins

(atorvastatin and simvastatin) and metformin obtained from a sample of 462,933 UK Biobank

participants using interviews, self-reporting and medical records (UK Biobank Data-Field

20003), to inform the interpretation of metabolite results. These medication outcomes also

served as positive controls, with liability to CAD expected to most strongly raise statin use, and

liability to T2D expected to most strongly raise metformin use.

For the purposes of further examining distortions by medication use, we used metabolite GWAS

on the same sample which were divided into age tertiles (containing ages: 39-53 years, 53-61

years, and 61-73 years), and which used the same standardisations and covariate adjustments.

Based on previous work in UK Biobank,(49) the estimated prevalence of statin medication use

within these same tertiles (youngest to oldest) is 5%, 17%, and 29%, respectively.

Data used for additional outcomes (adiposity, smoking and alcohol consumption) is described in

Supplementary File.

Statistical approach

To generate MR estimates of the effect of genetic liability to T2D and CAD on metabolites (with

ages combined and within age tertiles), and on medication use and additional outcomes noted

above, we integrated estimates of the association of SNPs with exposures (T2D and CAD

separately), with estimates of the association of those same SNPs with each metabolic trait

measured in UK Biobank. Summary statistics were harmonised using the 'harmonise_data'

function within the TwoSampleMR package.(50) Using the same package, we used inverse

variance weighted (IVW) regression in the main analysis, which assumes that none of the SNPs

are pleiotropic (exclusion restriction), as well as the two other core IV assumptions: relevance

and independence.(51) To examine and correct for potential horizontal pleiotropy, we used 3

additional sensitivity methods for each exposure-outcome pair: MR-Egger (which allows for all

SNPs to be pleiotropic),(52) weighted median (which allows for up to half of the weighted SNPs

to be pleiotropic and is less influenced by outliers than other models)(51), and the weighted

mode (which assumes that the most common effect is consistent with the true causal effect, i.e.

not biased by horizontal pleiotropy).(53) To aid interpretation, all estimates and standard errors

were multiplied by 0.693 ($\log_e2$) and represent the normalised SD unit difference in each

outcome trait (metabolites, medications, adiposity, smoking, and alcohol) per doubling of

genetic liability to T2D or CAD, based on previous recommendations(54). Statistical analyses

were performed in R version 4.0.2.

RESULTS

Instrument count and strength are reported in **Supplementary File**.

Lipids and lipoproteins

IVW estimates for the effect of higher liability to T2D and to CAD on lipids tended to differ

between diseases (**Figure 1**). Higher T2D liability was estimated to decrease total, HDL-C and

LDL-C (e.g., HDL-C -0.05 SD; 95% CI -0.07, -0.03), with no strong evidence of an effect on

VLDL-C. IVW estimates for CAD liability on cholesterol were less precise but suggested an

effect on lowering HDL-C and raising total-C, VLDL-C and LDL-C. T2D liability appeared to

increase all triglyceride groups (e.g., triglycerides in VLDL 0.04 SD; 95% CI 0.01, 0.07), whilst

CAD liability had little effect on triglyceride groups except for LDL triglycerides which were

increased. T2D liability was estimated to increase VLDL particle size (0.04 SD; 95% CI 0.02,

0.07), and decrease LDL and HDL particle size (-0.04 SD; 95% CI -0.06, -0.02 for both), whilst

CAD liability was estimated to increase LDL particle size (0.06 SD; 95% CI 0.02, 0.10), and

decrease HDL particle size (-0.06 SD; 95% CI -0.11, -0.01). T2D liability appeared to decrease,

whilst CAD liability appeared to increase, apolipoprotein B, although estimates were imprecise

for CAD; whilst liability to either disease appeared to decrease apolipoprotein A1 (T2D -0.03

SD; 95% CI -0.05, -0.01; CAD -0.07 SD; 95% CI -0.11, -0.03). Effect estimates across

sensitivity models were imprecise for T2D and CAD with each lipid trait (e.g., MR Egger

estimate for effect liability to T2D on total-C 0.00 SD; 95% CI -0.05, 0.04; Egger P-values largely

>0.05). Of note, the effect of higher CAD liability appeared inverse for VLDL-C, LDL-C, and

apolipoprotein B in weighted median and weighted mode models (**Supplementary Tables 2-4;**

Supplementary Figure 6). Evidence of heterogeneity was strong for all lipid and lipoprotein

traits, e.g., Cochran's Q P-value = $4.22e^{-188}$ for the IVW estimate for T2D liability on total-C

(**Supplementary Table 2**). Where the direction of effect estimates was inconsistent across MR

models, we examined scatter plots of individual SNP effects (**Supplementary Figure 4**). These

supported the existence of several outlier SNPs which were biasing estimates from IVW and

MR Egger models; estimates from weighted median and weighted mode models appeared not

to be influenced by these outliers and were in line with the majority of SNP effects.

The magnitudes of the effect of liability to T2D or CAD on statin or metformin use were small. As

expected, higher T2D liability most strongly increased odds of taking metformin

(**Supplementary Figure 1**; OR 1.02; 95% CI 1.01, 1.02), whilst higher CAD liability

most strongly increased odds of taking simvastatin (OR 1.03; 95% CI 1.03, 1.04). The effect of

higher T2D liability on metformin use was robust across weighted median and weighted mode

models but attenuated in the MR-Egger model (Egger intercept P-value=$6.09e^{-16}$

(**Supplementary Tables 3&4; Supplementary Figure 5**)). Estimates of CAD liability for

atorvastatin and simvastatin use were consistent across sensitivity models (**Supplementary**

Table 2).

The estimated effects of T2D and CAD liability on several lipids, particularly non-HDL

cholesterol, differed markedly by age (**Figure 2**). Among these age-stratified results, some

estimated effects of T2D liability on lipids were inconsistent across sensitivity models, including

for apolipoprotein B and LDL-C (**Supplementary Figure 7**), however, there was little evidence

that Egger intercepts for these estimates differed from zero (**Supplementary Table 6**). Based

on outlier-robust weighted median and mode models, higher CAD liability was estimated to

decrease LDL-C and apolipoprotein B within the oldest age tertile (statin use 29%); these

effects diminished within the intermediate age tertile (statin use 17%) and were null within the

youngest age tertile (statin use 5%).

Fatty acids and amino acids

Effects on fatty acid traits were largely opposite for T2D liability and CAD liability (**Figure 3**). For

example, higher T2D liability was estimated to decrease the ratio of docosahexaenoic acid to

total fatty acids (-0.02 SD; 95% CI -0.03, -0.01) whereas CAD liability was estimated to increase

the same ratio (0.03 SD; 95% CI 0.00, 0.05). CAD liability was estimated to decrease the ratio

of saturated to total fatty acids, and increase the ratio of docosahexaenoic acid to total fatty

acids, and both of these were consistent across sensitivity models. Higher T2D liability was

estimated to increase all amino acids (except for glycine), including total BCAAs (IVW 0.05 SD;

95% CI 0.04, 0.07), which was robustly positive across sensitivity models (**Supplementary

Figure 5**). There was consistently little evidence of an effect of CAD liability on any amino acid,

except for total BCAAs and valine for which MR-Egger estimates suggested a decrease

(**Supplementary Tables 2-4; Supplementary Figure 7**). Evidence of heterogeneity was strong

for most fatty acid and amino acid traits (**Supplementary Table 2**).

The effects of T2D liability on fatty acids and amino acids as estimated by IVW models were

fairly consistent with age, exceptions including total fatty acids, ratio of saturated to total fatty

acids, and histidine (**Figure 4**). For histidine, estimates were consistently null in the intermediate

tertile, and consistently positive in the oldest and youngest tertiles (**Supplementary Tables 5-**

7). The effect of higher CAD liability on total fatty acids decreased with age, with the youngest

tertile exhibiting an increase, the intermediate tertile a null effect, and the oldest tertile a

decrease (**Supplementary Table 5**). The effect of higher CAD liability on both omega-3 to total

fatty acids and docosahexaenoic acid to total fatty acids ratios was null in the youngest tertile

but positive in both the intermediate and oldest tertiles (consistent across sensitivity models

(**Supplementary Tables 5-7**)).

Glycolysis traits and other metabolites

As expected, T2D liability consistently increased glucose (0.08 SD; 95% CI 0.06, 0.10) across

sensitivity models (**Supplementary Tables 2-4; Supplementary Figure 5**); yet there was no

effect of CAD liability on glucose. There was little evidence of effect of T2D liability or CAD

liability on other glycolysis related metabolites, ketone bodies or fluid balance metabolites

(**Figure 5**). Only T2D liability was estimated to slightly increase glycoprotein acetyls (IVW 0.02

SD; 95% CI 0.00, 0.04), although there were inconsistencies across models (**Supplementary**

Figure 5). Effect estimates for CRP were similar to those for glycoprotein acetyls. Evidence of

heterogeneity was strong for most pre-glycaemic and other metabolic traits (**Supplementary**

Table 2).

Estimates of the effects of T2D and CAD liability were largely consistent across age tertiles for

glycolysis traits and ketone bodies, except for CAD liability on lactate and pyruvate which was

positive in the youngest and null in the intermediate and oldest tertiles (**Figure 6**). The effect of

higher T2D liability on glycoprotein acetyls was positive in the youngest (IVW 0.04 SD, 95% CI

0.02, 0.06) and null in the oldest tertile. This was not robust across sensitivity models

(**Supplementary Tables 6-7; Supplementary Figure 9**)**.**

Adiposity, smoking, and alcohol consumption

Higher genetic liability to T2D was estimated to increase all adiposity outcomes according to

IVW estimates (**Supplementary Figure 2**; e.g., BMI: 0.03 SD; 95% CI 0.01, 0.05). However,

there was evidence to suggest those estimates may be biased by horizontal pleiotropy; MR-

Egger P-values were <0.05 for all adiposity traits (**Supplementary Table 3**). There was little

evidence of an effect of liability to CAD on any of the adiposity outcomes according to IVW,

weighted median and weighted mode estimates, however MR-Egger estimates suggested a

small effect on decreased adiposity (e.g., fat mass: -0.03 SD; 95% CI -0.07, 0.00). Evidence of

heterogeneity was strong for all adiposity traits (**Supplementary Table 2**). The effects of T2D

and CAD liability on both smoking status and alcohol drinking status were null (**Supplementary**

Figure 3). Higher T2D liability was estimated to increase alcohol intake frequency in IVW

models (0.02 SD, 95% CI 0.01, 0.04); this was null in sensitivity models (**Supplementary**

Tables 3&4). Higher CAD liability had no effect on alcohol intake frequency. There was no

effect of liability to either disease on pack years of smoking.

Summary XY plot of T2D and CAD liability for metabolic and other outcomes

Estimates of the effects of T2D and CAD liability on each metabolite (ages combined), adiposity,

and medication use were visualized in an XY plot to compare the overall pattern of effects of

liability to either disease across outcomes (**Figure 7**). To better visualize the comparison across

different feature classes, only a subset of metabolites is included on the XY plot (the same as

included across **Figures 1-6**); the slope of this regression line was -0.16 with an R^2 of 0.02.

When including all 266 features (all metabolites, adiposity, smoking, alcohol, CRP), the slope of

the regression line was -0.49 with an R^2 of 0.11. Together, this indicates a weak association

between profiles, giving further evidence that genetic liability to T2D and to CAD have distinct

metabolic features.

DISCUSSION

In this study, we directly compared the metabolic profiles of genetic liability to T2D and CAD,

two diseases which commonly co-occur but which involve different pathophysiology and clinical

presentation. We applied a reverse-MR framework(38) using new summary-level GWAS data

on metabolomics from UK Biobank, which enabled a 5-times larger sample size over previous

studies.(39,40) Our results based on pleiotropy-robust models suggest that genetic liability to

T2D and to CAD have largely distinct metabolic features, including increased BCAAs in T2D

and decreased LDL-C and apolipoprotein B in CAD. Such apparently favourable effects of CAD

liability differ substantially by age and likely reflect mediation by statin use in adulthood.

Statins and metformin are commonly used for the prevention/treatment of CAD and T2D,

respectively. The overall prevalence of statin use in UK Biobank is 16%, with men almost twice

as likely to be taking statins as women, and use increasing markedly across age tertiles.(49)

Statins and metformin are known to lower LDL-C (46,55) and will likely have direct and indirect

effects on other metabolic traits.(47) As expected, our results suggest that increased T2D

liability most strongly increases the odds of metformin use whilst increased CAD liability most

strongly increases the odds of statin use, providing positive controls and suggesting specificity

of genetic instruments used for each disease. Medication use may therefore modify the effect of

T2D or CAD liability on metabolic traits and distort results in the form of underestimated, or even

reversed, effects of genetic liability. Our results based on (non-pleiotropy-robust) IVW models

suggest that higher CAD liability increases LDL-C and apolipoprotein B which is consistent with

a previous reverse-MR conducted across younger samples,(40) suggesting that perturbations in

LDL-C in early life due to CAD liability persist into adulthood. We did, however, see attenuation

of these effects in the oldest age tertile which could be due to the increased statin use in the

older sample; and the direction of effect was inconsistent across pleiotropy-robust sensitivity

models, suggesting that these particular results were vulnerable to outlier SNP effects. Results

based on pleiotropy/outlier-robust weighted median and mode models suggested that CAD

liability has an inverse effect on LDL-C, VLDL-C, and apolipoprotein B; this again differed

substantially by age, with inverse effects only at older ages, and with attenuated or null effects

at younger ages. Medication use may explain inconsistencies between results for T2D or CAD

liability and LDL-C from this study and previous studies, particularly studies of younger people

who are less likely to be taking medication.(40,56) By stratifying the cohort by age as a proxy for

medication use before performing metabolite GWAS, we were likely better positioned to

overcome these distortions and isolate the effects of disease liability. Conditioning on age (as a

proxy) instead of medication use itself, which is affected by disease liability, also reduced the

potential for collider bias.

Increasing HDL-C has been hypothesized as a mechanism to reduce CAD risk, based largely

on conventional non-genetic epidemiology studies.(57) However, evidence from MR studies has

shown that HDL-C-raising genetic variants do not reduce CAD risk,(37,58) and a meta-analysis

showed that that HDL-C modifying treatments did not reduce cardiovascular mortality.(59) Our

current study detected an effect of CAD liability on decreasing HDL-C levels, suggesting that

reduced HDL-C is an early (likely non-causal) feature of CAD development, potentially

explaining why lower HDL-C appears to be associated with higher CAD risk in observational

settings. We also found some evidence to suggest that both LDL-C and HDL-C are reduced in

response to increased T2D liability, which is consistent with evidence from a previous reverse-

MR study among young people for HDL-C but not LDL-C (which was raised),(39) and a

conventional 'forward'-MR study that found increased HDL-C and LDL-C decreased risk of

T2D.(36) This is also in accordance with evidence that statin therapy (which lowers LDL-C)

increases risk of T2D.(60) However, there were inconsistencies in estimates for effect on these

traits across pleiotropy-robust sensitivity models.

Our results suggest that T2D and CAD liability confer opposite effects on fatty acid metabolism,

which were largely consistent across pleiotropy/outlier-robust sensitivity models. Inverse effects

of T2D liability on various fatty acid metabolites (e.g., omega-6 and polyunsaturated) support

them as potential candidates for further functional studies into their role in protection against

T2D. However, a systematic review of randomized controlled trials of polyunsaturated fatty acid

supplementation found no strong evidence that increasing omega-3, omega-6 or total

polyunsaturated fatty acids provided protection against or treated T2D.(61) We observed an

effect of higher CAD liability on increasing ratios of omega-3 fatty acids and docosahexaenoic

acids to total fatty acids. This contrasts with existing evidence of a protective effect of omega-3

fatty acids on cardiovascular outcomes.(62) We saw evidence of substantial age differences in

these effects, where higher CAD liability increased these ratios in the older tertiles but not the

youngest, which could be an effect of medication or improved lifestyle in response to a CAD

diagnosis.

Consistent with previous studies, we found consistent evidence across ages and sensitivity

models that T2D liability robustly increased total BCAAs(17,39) whereas there was no evidence

of an effect of CAD liability on BCAAs, highlighting that increased total BCAAs are exclusively a

feature of T2D liability. Although both T2D and CAD are associated with inflammation,(63)

evidence of an effect on levels of glycoprotein acetyls from this study was not robust for liability

to either disease when viewing ages collectively; however, higher T2D liability did appear to

modestly raise glycoprotein acetyls within the youngest age group. It is difficult to draw

conclusions about the role of inflammation in either disease process from our study, however,

given that we only considered two inflammatory markers, omitting other potentially important

ones such as interleukin-6 and interleukin-1β that may play a role in disease

pathogenesis.(64,65)

It is well established that excess adiposity is a causal risk factor for T2D,(66) and there is strong

causal evidence that adiposity increases CAD risk in conventional (forward-direction) MR

studies(67). Presently, we did not find consistent evidence that either T2D or CAD liability raises

adiposity. This likely reflects the more distal nature of adiposity as compared with circulating

metabolites, and possibly highly pleiotropic variants among the outcome SNPs.(68) We also did

not find consistent evidence that either T2D or CAD liability increases smoking or alcohol

behaviours. Although increased smoking and drinking are risk factors for both T2D and

CAD,(69,70) the lack of signal seen in our study suggests that they are more distal features of

disease liability. This provides further evidence that the reverse-MR approach is useful for

revealing more proximal factors such as metabolites that are directly involved in the disease

process and highlights the importance of combining evidence from MR study designs in different

directions to reveal the full scope of factors contributing to disease development.

Study limitations

The samples used to generate genetic instruments for T2D and CAD included participants from

UK Biobank, the same sample from which we obtained genetic association estimates for

metabolic traits, medication use, and lifestyle-related outcomes (~26% and ~48% overlap,

respectively). This may have led to bias in the results in the direction of the observational

association, however, given the strong genetic instruments for T2D and CAD liability, bias from

sample overlap is likely small.(71) Another limitation is the unrepresentative nature of UK

Biobank (initial response rate ~5%) and therefore is vulnerable to various forms of selection

bias. Replication of this study in other large cohort studies and application of different

approaches will allow more robust metabolic characterisation of T2D and CAD liability, although

UK Biobank is currently the largest such data in existence. The metabolite GWAS with all ages

collectively was not age-adjusted, leaving the potential for distortions by age within those

metabolite effect estimates; although we were able to additionally examine these effects within

age tertiles. Use of only summary-level data limits the capacity to fully explore effects of other

factors such as medication use, sex, and ethnicity, which may influence metabolites. A further

limitation is the reliance on targeted NMR metabolomics, rather than mass spectrometry which

is not yet available at large scale but offers a broader representation of metabolites beyond lipid

subclasses; targeted NMR is often considered more clinically relevant, however. The smoking

pack-years GWAS was restricted to ever-smokers, which may induce sampling bias and

invalidate the MR assumptions for that analysis.

Conclusions

Our results support largely distinct metabolic profiles of genetic liability to T2D and to CAD using

metabolite GWAS data from the largest cohort to date. Our most robust findings, based on

pleiotropy-robust sensitivity models, suggest that T2D liability increases BCAAs, whilst CAD

liability decreases LDL-C and apolipoprotein B. Such apparently favourable effects of CAD

liability differ substantially by age and likely reflect mediation by statin use in adulthood.

ACKNOWLEDGEMENTS

We thank the participants of the UK Biobank study and the genome-wide association study

consortiums who made their summary statistics publicly available for this study.

SOURCES OF FUNDING

This research was funded in whole, or in part, by the Wellcome Trust [218495/Z/19/Z]. For the

purpose of Open Access, the author has applied a CC BY public copyright licence to any Author

Accepted Manuscript version arising from this submission. MLS is supported by the Wellcome

Trust through a PhD studentship [218495/Z/19/Z]. CJB, MVH, GDS, JAB and ELA work in a unit

funded by the UK MRC (MC_UU_00011/1; MC_UU_00011/4) and the University of Bristol. CJB

is supported by Diabetes UK (17/0005587) and the World Cancer Research Fund (WCRF UK),

as part of the World Cancer Research Fund International grant program (IIG_2019_2009). CJB

and MLS acknowledge funding from the Wellcome Trust (202802/Z/16/Z).

DISCLOSURES

MVH has collaborated with Boehringer Ingelheim in research, and in adherence to the

University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CSTU) staff

policy, did not accept personal honoraria or other payments from pharmaceutical companies.

MVH became an employee of 23andMe during the study. No other conflicts of interest to

declare.

DATA AVAILABILITY

All summary level GWAS results are publicly available through the IEU-OpenGWAS platform,

accessible at https://gwas.mrcieu.ac.uk/.

AUTHOR CONTRIBUTIONS

JAB, ELA and CJB conceived and planned the study and supervised analyses. MLS conducted

the analyses and wrote the first draft. All others critically reviewed the intellectual content of

manuscript drafts and with MLS approved the final version for submission.

REFERENCES

1.   International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium; 2019.
2.   Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, Alkatheeri R, et al.
Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of
Disease Study. Cureus. 2020;

3. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-
mapping type 2 diabetes loci to single-variant resolution using high-density imputation
and islet-specific epigenome maps. Nature Genetics. 2018;50(11):1505–13.

4. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C. A comprehensive 1000 Genomes–
based genome-wide association meta-analysis of coronary artery disease. Nature Genetics.
2015;47(10):1121–30.

5. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine.
Molecular Case Studies. 2015;1(1):a000588.

6. Ottosson F, Smith E, Melander O, Fernandez C. Altered Asparagine and Glutamate
Homeostasis Precede Coronary Artery Disease and Type 2 Diabetes. The Journal of
Clinical Endocrinology & Metabolism. 2018;103(8):3060–9.

7. Urpi-Sarda M, Almanza-Aguilera E, Llorach R, Vázquez-Fresno R, Estruch R, Corella D,
et al. Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-
sectional study of PREDIMED trial participants. Diabetes & Metabolism.
2019;45(2):167–74.

8. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-GonzálezGonz MA, Salas-
SalvadóSalvad J, et al. Metabolomics in Prediabetes and Diabetes: A Systematic Review
and Meta-analysis. Diabetes Care. 2016;(39):833–46.

9. Ahola-Olli A V., Mustelin L, Kalimeri M, Kettunen J, Jokelainen J, Auvinen J, et al.
Circulating metabolites and the risk of type 2 diabetes: A prospective study of 11,896
young adults from four Finnish cohorts. Diabetologia. 2019;2298–309.

10. Al-Sulaiti H, Diboun I, Agha M V., Mohamed FFS, Atkin S, Dömling AS, et al.
Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. Journal of
Translational Medicine. 2019;17(1):1–11.

11. Concepcion J, Chen K, Saito R, Gangoiti J, Mendez E, Nikita ME, et al. Identification of
pathognomonic purine synthesis biomarkers by metabolomic profiling of adolescents with
obesity and type 2 diabetes. PLOS ONE. 2020;15(6):e0234970.

12. Gu X, Al Dubayee M, Alshahrani A, Masood A, Benabdelkamel H, Zahra M, et al.
Distinctive Metabolomics Patterns Associated With Insulin Resistance and Type 2
Diabetes Mellitus. Frontiers in Molecular Biosciences. 2020;7.

13. Liu J, Semiz S, van der Lee SJ, van der Spek A, Verhoeven A, van Klinken JB, et al.
Metabolomics based markers predict type 2 diabetes in a 14-year follow-up study.
Metabolomics. 2017 Sep 28;13(9):104.

14. Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance
and type 2 diabetes: progress from the metabolome. The Lancet Diabetes &
Endocrinology. 2014 Jan 1;2(1):65–75.

15. Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, et al. Metabolic
Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological
Setting. Breant B, editor. PLoS ONE. 2010 Nov 11;5(11):e13953.

16. Bos MM, Noordam R, Bennett K, Beekman M, Mook-Kanamori DO, Willems Van Dijk
K, et al. Metabolomics analyses in non-diabetic middle-aged individuals reveal
metabolites impacting early glucose disturbances and insulin sensitivity. Metabolomics.
2020;16(3).

17. Sun Y, Gao HY, Fan ZY, He Y, Yan YX. Metabolomics Signatures in Type 2 Diabetes: A
Systematic Review and Integrative Analysis. The Journal of Clinical Endocrinology &
Metabolism. 2020;105(4):1000–8.

18. Li Y, Zhang D, He Y, Chen C, Song C, Zhao Y, et al. Investigation of novel metabolites
potentially involved in the pathogenesis of coronary heart disease using a UHPLC-
QTOF/MS-based metabolomics approach. Scientific Reports. 2017;7(1).
19. Smith E, Ottosson F, Hellstrand S, Ericson U, Orho-Melander M, Fernandez C, et al.
Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular
disease. Heart. 2020;106(9):691–7.
20. Tzoulaki I, Castagné R, Boulangé CL, Karaman I, Chekmeneva E, Evangelou E, et al.
Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent
cardiovascular disease. European Heart Journal. 2019;40(34):2883–96.
21. Amin AM, Mostafa H, Arif NH, Abdul Kader MAS, Kah Hay Y. Metabolomics profiling
and pathway analysis of human plasma and urine reveal further insights into the
multifactorial nature of coronary artery disease. Clinica Chimica Acta.
2019;493(January):112–22.
22. Li R, Li F, Feng Q, Liu Z, Jie Z, Wen B, et al. An LC-MS based untargeted metabolomics
study identified novel biomarkers for coronary heart disease. Molecular BioSystems.
2016;12(11):3425–34.
23. Basak T, Varshney S, Hamid Z, Ghosh S, Seth S, Sengupta S. Identification of metabolic
markers in coronary artery disease using an untargeted LC-MS based metabolomic
approach. Journal of Proteomics. 2015;127:169–77.
24. Fan Y, Li Y, Chen Y, Zhao YJ, Liu LW, Li J, et al. Comprehensive Metabolomic
Characterization of Coronary Artery Diseases. J Am Coll Cardiol. 2016;68(12):1281–93.
25. Vernon ST, Tang O, Kim T, Chan AS, Kott KA, Park J, et al. Metabolic Signatures in
Coronary Artery Disease: Results from the BioHEART-CT Study. Cells. 2021;10(5):980.
26. Wang Z, Zhu C, Nambi V, Morrison AC, Folsom AR, Ballantyne CM, et al. Metabolomic
Pattern Predicts Incident Coronary Heart Disease. Arteriosclerosis, Thrombosis, and
Vascular Biology. 2019;39(7):1475–82.
27. Gao X, Ke C, Liu H, Liu W, Li K, Yu B, et al. Large-scale Metabolomic Analysis Reveals
Potential Biomarkers for Early Stage Coronary Atherosclerosis. Scientific Reports.
2017;7(1).
28. Xu X, Gao B, Guan Q, Zhang D, Ye X, Zhou L, et al. Metabolomic profile for the early
detection of coronary artery disease by using UPLC-QTOF/MS. Journal of
Pharmaceutical and Biomedical Analysis. 2016;129:34–42.
29. Wurtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, et al. High-
throughput quantification of circulating metabolites improves prediction of subclinical
atherosclerosis. European Heart Journal. 2012;33(18):2307–16.
30. Mehta A, Liu C, Nayak A, Tahhan AS, Ko YA, Dhindsa DS, et al. Untargeted high-
resolution plasma metabolomic profiling predicts outcomes in patients with coronary
artery disease. PLOS ONE. 2020;15(8):e0237579.
31. Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline
metabolomic profiles predict cardiovascular events in patients at risk for coronary artery
disease. American Heart Journal. 2012;163(5):844-850.e1.
32. Karagiannidis E, Sofidis G, Papazoglou AS, Deda O, Panteris E, Moysidis D V, et al.
Correlation of the severity of coronary artery disease with patients' metabolic profile-
rationale, design and baseline patient characteristics of the CorLipid trial. BMC
Cardiovascular Disorders. 2021;21(1).

33.   Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
555   contribute to understanding environmental determinants of disease? International Journal
556   of Epidemiology. 2003;32(1):1–22.

557   34.   Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of
558   Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in
559   Life on the Risk of Coronary Heart Disease. J Am Coll Cardiol. 2012;60(25):2631–9.

560   35.   Holmes M V, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al.
561   Mendelian randomization of blood lipids for coronary heart disease. European Heart
562   Journal. 2015;36(9):539–50.

563   36.   White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, et al.
564   Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.
565   JAMA Cardiology. 2016;1(6):692.

566   37.   Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G,
567   et al. Evaluating the relationship between circulating lipoprotein lipids and
568   apolipoproteins with risk of coronary heart disease: A multivariable Mendelian
569   randomisation analysis. PLOS Medicine. 2020;17(3):e1003062.

570   38.   Holmes M V, Davey Smith G. Can Mendelian Randomization Shift into Reverse Gear?
571   Clinical Chemistry. 2019;65(3):363–6.

572   39.   Bell JA, Bull CJ, Gunter MJ, Carslake D, Mahajan A, Davey Smith G, et al. Early
573   Metabolic Features of Genetic Liability to Type 2 Diabetes: Cohort Study With Repeated
574   Metabolomics Across Early Life. Diabetes Care. 2020;43(7):1537–45.

575   40.   Battram T, Hoskins L, Hughes DA, Kettunen J, Ring SM, Smith GD, et al. Coronary
576   artery disease, genetic risk and the metabolome in young individuals. Wellcome Open
577   Research. 2019;3:114.

578   41.   Hartwig FP, Tilling K, Davey Smith G, Lawlor DA, Borges MC. Bias in two-sample
579   Mendelian randomization when using heritable covariable-adjusted summary associations.
580   International Journal of Epidemiology. 2021;

581   42.   Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for
582   cardiovascular research. European Heart Journal. 2019;40(14):1158–66.

583   43.   Haworth S, Mitchell R, Corbin L, Wade KH, Dudding T, Budu-Aggrey A, et al. Apparent
584   latent structure within the UK Biobank sample has implications for epidemiological
585   analysis. Nature Communications. 2019 Dec 18;10(1):333.

586   44.   Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
587   access resource for identifying the causes of a wide range of complex diseases of middle
588   and old age. PLoS Med. 2015/04/01. 2015;12(3):e1001779.

589   45.   Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
590   Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale
591   Epidemiology: A Primer on -Omic Technologies. American Journal of Epidemiology.
592   2017;186(9):1084–96.

593   46.   Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-
594   density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from
595   genetic, epidemiologic, and clinical studies. A consensus statement from the European
596   Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459–72.

597   47.   Würtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, et al. Metabolomic
598   Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J Am Coll
599   Cardiol. 2016;67(10):1200–10.

48. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes M V, Engmann JEL, Shah T, et al.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from
genetic analysis and randomised trials. The Lancet. 2015;385(9965):351–61.
49. Bell JA, Richardson TG, Wang Q, Sanderson E, Palmer T, Walker V, et al. Dominant role
of abdominal adiposity in circulating lipoprotein, lipid, and metabolite levels in UK
Biobank: Mendelian randomization study. medRxiv. 2021 Jan 1;2021.05.29.21258044.
50. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
platform supports systematic causal inference across the human phenome. Elife. 2018;7.
51. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian
randomization with some invalid instruments using a weighted median estimator. Genetic
Epidemiology. 2016;under revi:Available at: https://www.academia.edu/15479132/Co.
52. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
effect estimation and bias detection through Egger regression. International Journal of
Epidemiology. 2015;44(2):512–25.
53. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017/10/19.
2017;
54. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable:
interpretation and presentation of causal estimates. European Journal of Epidemiology.
2018 Oct 23;33(10):947–52.
55. Solymár M, Ivic I, Pótó L, Hegyi P, Garami A, Hartmann P, et al. Metformin induces
significant reduction of body weight, total cholesterol and LDL levels in the elderly – A
meta-analysis. PLOS ONE. 2018;13(11):e0207947.
56. März W, Scharnagl H, Winkler K, Tiran A, Nauck M, Boehm BO, et al. Low-density
lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion
molecules, and angiographic coronary artery disease: The Ludwigshafen Risk and
Cardiovascular Health Study. Circulation. 2004;110(19):3068–74.
57. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic
cardiovascular disease. Nature Reviews Drug Discovery. 2005;4(3):193–205.
58. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et
al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation
study. Lancet. 2012/05/23. 2012;380(9841):572–80.
59. Riaz H, Khan SU, Rahman H, Shah NP, Kaluski E, Lincoff AM, et al. Effects of high-
density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review
and meta-analysis. European Journal of Preventive Cardiology. 2019;26(5):533–43.
60. Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use
and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open
Diabetes Research & Care. 2017;5(1):e000438.
61. Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L. Omega-3, omega-6,
and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes
mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ.
2019;l4697.
62. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al. Effect of
omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis.
EClinicalMedicine. 2021;38:100997.

63. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G,
Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future
Perspectives. Eur Cardiol. 2019 Apr;14(1):50–9.
64. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a
mendelian randomisation analysis. The Lancet. 2012;379(9822):1214–24.
65. Ridker PM, Everett BM, Thuren T, Macfadyen JG, Chang WH, Ballantyne C, et al.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England
Journal of Medicine. 2017;377(12):1119–31.
66. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al.
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be
Individualized? Diabetes Care. 2011;34(6):1424–30.
67. Lv WQ, Zhang X, Fan K, Xia X, Zhang Q, Liu HM, et al. Genetically driven adiposity
traits increase the risk of coronary artery disease independent of blood pressure,
dyslipidaemia, glycaemic traits. European Journal of Human Genetics. 2018;26(10):1547–
53.
68. Corbin LJ, Richmond RC, Wade KH, Burgess S, Bowden J, Smith GD, et al. BMI as a
Modifiable Risk Factor for Type 2 Diabetes: Refining and Understanding Causal
Estimates Using Mendelian Randomization. Diabetes. 2016;65(10):3002–7.
69. Chi Y, Wang X, Jia J, Huang T. Smoking Status and Type 2 Diabetes, and Cardiovascular
Disease: A Comprehensive Analysis of Shared Genetic Etiology and Causal Relationship
. Vol. 13, Frontiers in Endocrinology . 2022.
70. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol Consumption and
Cardiovascular Disease. Circulation: Genomic and Precision Medicine. 2020;13(3).
71. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample
Mendelian randomization. Genet Epidemiol. 2016/10/19. 2016;40(7):597–608.
671
672

Figure 1: Effect of T2D and CAD liability on lipids and lipoproteins. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to T2D or CAD based on IVW models.

Figure 2. Effect of T2D (a) and CAD (a) liability on lipids and lipoproteins in age tertiles. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to disease based on IVW models.

Figure 3: Effect of T2D and CAD liability on fatty acids and amino acids. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to T2D or CAD based on IVW models.

Figure 4. Effect of T2D (a) and CAD (b) liability on fatty acids and amino acids in age tertiles. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to disease based on IVW models.

Figure 5: Effect of T2D and CAD liability on glycolysis related metabolites, ketone bodies, fluid balance metabolites and inflammation metabolites. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to T2D or CAD based on IVW models.

Figure 6. Effect of T2D (a) and CAD (b) liability on glycolysis related metabolites, ketone bodies, fluid balance metabolites and glycoprotein acetyls in age tertiles. Effect estimates are normalised SD unit differences in metabolite per doubling of liability to disease based on IVW models.

Figure 7. Comparison of the effects of T2D and CAD liability on adiposity, metabolic traits, medication use, smoking and alcohol use. Effect estimates are SD unit differences in adiposity or metabolic trait, or logodds for medication use and smoking/alcohol status, per doubling of odds of T2D or CAD, based on IVW models.